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Abstract
Background: There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients
with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outcomes of AITL
patients undergoing an allo-HCT.
Methods: We evaluated 249 adult AITL patients who received their first allo-HCT during 2000–2016.
(Continued on next page)
* Correspondence: mhamadani@mcw.edu
2Center for International Blood and Marrow Transplant Research, Department
of Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Suite
C5500, 8701 W. Watertown Plank Rd, Milwaukee, WI 53226, USA
27Division of Hematology and Oncology, Department of Medicine, Medical
College of Wisconsin, 8701 Watertown Plank Rd. PO Box 26509, Milwaukee,
WI 53226, USA
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Epperla et al. Journal of Hematology & Oncology            (2019) 12:6 
https://doi.org/10.1186/s13045-018-0696-z
(Continued from previous page)
Results: The median patient age was 56 years (range = 21–77). Majority of the patients were Caucasians (86%), with a
male predominance (60%). Graft-versus-host disease (GVHD) prophylaxis was predominantly calcineurin inhibitor-based
approaches while the most common graft source was peripheral blood (97%). Median follow-up of survivors was
49 months (range = 4–170 months). The cumulative incidence of grade 2–4 and grade 3–4 acute GVHD at day 180 were
36% (95% CI = 30–42) and 12 (95% CI = 8–17), respectively. The cumulative incidence of chronic GVHD at 1 year was 49%
(95%CI 43–56). The 1-year non-relapse mortality (NRM) was 19% (95% CI = 14–24), while the 4-year relapse/progression,
progression-free survival (PFS), and overall survival (OS) were 21% (95% CI = 16–27), 49% (95% CI = 42–56), and 56% (95%
CI = 49–63), respectively. On multivariate analysis, chemoresistant status at the time of allo-HCT was associated with a
significantly higher risk for therapy failure (inverse of PFS) (RR = 1.73 95% CI = 1.08–2.77), while KPS < 90% was associated
with a significantly higher risk of mortality (inverse of OS) (RR = 3.46 95% CI = 1.75–6.87).
Conclusion: Our analysis shows that allo-HCT provides durable disease control even in AITL patients who failed a prior
auto-HCT and in those subjects with refractory disease at the time of allografting.
Keywords: Angioimmunoblastic T-cell lymphoma, Allogeneic transplantation, GVL effects,
Background
Angioimmunoblastic T-cell lymphoma (AITL) repre-
sents a distinct clinicopathologic entity among the
mature T- and NK-cell neoplasms, accounting for
approximately 1–2% of all non-Hodgkin lymphomas
(NHLs) [1, 2]. AITL patients typically present with
advanced stage disease, diffuse lymphadenopathy,
hepatosplenomegaly, systemic symptoms, and hyper-
gammaglobulinemia [3]. The clinical course is aggres-
sive and the disease generally carries a poor prognosis
even when treated with intensive induction regimens
[3]. Standard first-line therapy mostly consists of
anthracycline-based regimens with or without etopo-
side, based on the age [2, 4–6]. With this approach,
overall survival (OS) is a little over 30% at 5 years
[7]. In an attempt to improve the outcomes, autolo-
gous hematopoietic cell transplantation (auto-HCT)
consolidation has been applied in this patient popula-
tion [8–10]. While durable disease control can be
observed typically in patients in first complete remis-
sion (CR), the outcomes of AITL subjects in partial
remission (PR), and in those with refractory disease
or treated with ≥ 2 prior therapy lines, following
auto-HCT are less encouraging [10].
Allogeneic HCT (allo-HCT) may result in a lower
risk of relapse in part due to a graft-versus-lymphoma
effect mediated by the alloreactive donor cells [11–13].
Several retrospective studies [11, 14–16] have reported
excellent disease control with low rates of relapse and a
1-year non-relapse mortality (NRM) ranging from 8 to
25% with allo-HCT in AITL patients. However, these
analyses were done mainly in peripheral T-cell lymph-
oma (PTCL) patients with AITL as a subgroup or
reported only a small number of patients with AITL
(range N = 9–45 patients; Additional file 1: Table S1).
We report here a registry analysis, evaluating the out-
comes of patients with AITL undergoing allo-HCT.
Methods
Data sources
The Center for International Blood and Marrow Trans-
plant Research (CIBMTR) is a working group of more
than 500 transplantation centers worldwide that contrib-
ute detailed data on HCT to a statistical center at the
Medical College of Wisconsin (MCW). Participating
centers are required to report all transplantations con-
secutively and compliance is monitored by on-site au-
dits. Computerized checks for discrepancies, physicians’
review of submitted data, and on-site audits of partici-
pating centers ensure data quality. Observational studies
conducted by the CIBMTR are performed in compliance
with all applicable federal regulations pertaining to the
protection of human research participants. The MCW
and National Marrow Donor Program, Institutional
Review Boards approved this study.
The CIBMTR collects data at two levels: transplant
essential data (TED) and comprehensive report form
(CRF) data. TED data includes disease type, age, gender,
pre-HCT disease stage and chemotherapy-responsiveness,
date of diagnosis, graft type, conditioning regimen,
post-transplant disease progression and survival, develop-
ment of a new malignancy, and cause of death. All
CIBMTR centers contribute to TED data. More detailed
disease and pre- and post-transplant clinical information is
collected on a subset of registered patients selected for
CRF data by a weighted randomization scheme. TED- and
CRF-level data are collected pre-transplant, 100-days, and
6 months post-HCT and annually thereafter or until death.
Data for the current analysis were retrieved from CIBMTR
(TED and CRF) report forms.
Patients
Included in this analysis are adult (≥ 18 years) patients
with AITL, undergoing their first allo-HCT between 2000
and 2016. Eligible donors included either HLA-identical
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sibling donors or unrelated donors (URD) matched at the
allele-level at HLA-A, -B, -C, and -DRB1 and graft sources
included peripheral blood and bone marrow. Graft-versus-
host disease (GVHD) prophylaxis included both calcineurin
inhibitor (CNI) and non-CNI-based regimens. Recipients of
alternative donor transplantation were excluded due to
small numbers (haploidentical allografts, n = 8; mismatched
unrelated donor, n = 22; cord blood grafts, n = 21).
Definitions and study endpoints
The intensity of conditioning regimens was defined using
consensus criteria [17]. Disease response at the time of
HCT was determined using the International Working
Group criteria in use during the era of this analysis [18].
The primary endpoint was OS; death from any cause was
considered an event and surviving patients were censored
at last contact. Secondary endpoints included cumulative
incidence of acute GVHD, chronic GVHD, GVHD free,
relapse-free survival (GRFS), NRM, progression/relapse,
and progression-free survival (PFS). NRM was defined as
death without evidence of lymphoma progression/relapse;
relapse was considered a competing risk. Progression/re-
lapse was defined as progressive lymphoma after HCT or
lymphoma recurrence after a CR; NRM was considered a
competing risk. For PFS, a patient was considered treat-
ment failure at the time of progression/relapse or death
from any cause. Patients alive without evidence of disease
relapse or progression were censored at last follow-up.
Table 1 Baseline patient characteristics of patients with AITL
receiving first allo-HCT reported to the CIBMTR from 2000 to
2016
Variable N = 249 (%)
Median age at HCT, years (range) 56 (21–77)
Male gender 150 (60)
Race
Caucasian 214 (86)
African American 5 (2)
Othersa 17 (7)
Missing 13 (5)
Karnofsky performance score ≥ 90 119 (48)
< 90 113 (45)
Missing 17 (7)
HCT-CI
0 46 (18)
1–2 53 (21)
≥ 3 84 (34)
Not available before 2007 55 (22)
Missing 11 (4)
Interval from diagnosis to
HCT, months
Median (range) 14 (3–118)
Median lines of therapy
before HCT (range)
3 (1–5)
Remission status at HCT
Complete remission 108 (43)
Partial remission 90 (36)
Chemorefractory 38 (15)
Untreated/unknown 13 (5)
History of prior autologous
HCT
98 (39)
TBI in conditioning 83 (34)
ATG/alemtuzumab in
conditioningb
59 (24)
Conditioning intensityc
Myeloablative conditioning 66 (27)
Non-myeloablative/RIC 183 (73)
Graft source
Bone marrow 8 (3)
Peripheral blood 241 (97)
Donor type
HLA-identical sibling 140 (56)
Unrelated donor 8/8 109 (44)
Donor/recipient CMV status
Both negative 72 (29)
Both positive 59 (24)
Either donor/recipient + 69 (28)
Table 1 Baseline patient characteristics of patients with AITL
receiving first allo-HCT reported to the CIBMTR from 2000 to
2016 (Continued)
Variable N = 249 (%)
Missing 49 (19)
Graft-versus-host disease prophylaxis
Calcineurin inhibitor + MTX ± othersd
(except MMF)
119 (48)
Calcineurin inhibitor + MMF ± othersd 76 (31)
Calcineurin inhibitor + others (except
MMF)
40 (16)
Othersd 10 (4)
Missing 4 (2)
Year of HCT
2000–2006 47 (19)
2007–2011 82 (33)
2012–2016 120 (48)
Median follow-up of survivors (range), months 49 (4–170)
ATG antithymocyte globulin, CMV cytomegalovirus, HCT hematopoietic cell
transplantation, HCT-CI HCT-Comorbidity index, MMF mycophenolate mofetil,
MTX methotrexate, TBI total body irradiation, RIC reduced
intensity conditioning
aOthers: 13 Asian; 3 Hispanic or Latino; 1 race unspecified, non-Hispanic
bATG/alemtuzumab—49 ATG alone; 10 alemtuzumab alone
cFor details, refer to Additional file 1: Table S4
dFor details, refer to Additional file 1: Table S5
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Acute GVHD [19] and chronic GVHD [20] were graded
using standard criteria. Neutrophil recovery was defined as
the first of three successive days with absolute neutrophil
count (ANC) ≥ 500/μL after post-transplantation nadir.
Platelet recovery was defined as achieving platelet counts ≥
20,000/μL for at least 3 days, unsupported by transfusion.
For neutrophil and platelet recovery, death without the
event was considered a competing risk. The causes of death
are reported in accordance to the methodology described
previously [21].
Statistical analysis
Probabilities of PFS and OS were calculated using the
Kaplan–Meier estimates. Cumulative incidence of NRM,
lymphoma progression/relapse, and GVHD were calculated
to accommodate for competing risks. Associations among
patient-, disease-, and transplantation-related variables and
outcomes of interest were evaluated using Cox proportional
hazards regression. A stepwise model-building approach
Table 2 Univariate Analysis
Outcomes N Eval Prob (95% CI)
Neutrophil engraftment 236
1-year 97 (94–99)%
2-year 97 (94–99)%
Platelet recovery 218
1-year 91 (87–94)%
2-year 91 (87–95)%
Acute GVHD (II-IV) 239
180-day 36 (30–42)%
Acute GVHD (III-IV) 229
180-day 12 (8–17)%
Chronic GVHD 230
1-year 49 (43–56)%
2-year 58 (51–64)%
Extensive cGVHD 230
1-year 39 (33–46)%
2-year 46 (39–53)%
GRFS 230
1-year 35 (29–41)%
2-year 27 (21–33)%
NRM 249
1-year 19 (14–24)%
2-year 25 (20–31)%
4-year 30 (24–36)%
Progression/relapse 249
1-year 15 (11–20)%
2-year 19 (15–25)%
4-year 21 (16–27)%
PFS 249
1-year 66 (60–72)%
2-year 56 (49–62)%
4-year 47 (41–54)%
Overall survival 249
1-year 73 (68–79)%
2-year 63 (56–69)%
4-year 56 (49–63)%
GVHD graft-versus-host disease, Prob probability, CI confidence interval, N
number, NRM non-relapse mortality, PFS progression-free survival, GRFS GVHD
free, relapse-free survival
Probabilities of acute GVHD, chronic GVHD, treatment-related mortality and
progression/relapse were calculated using the cumulative incidence estimate.
Progression-free survival and overall survival was calculated using the Kaplan-
Meier product limit estimate
Univariate analysis of alternative donor sources is shown in Additional file 1
Table S6
Table 3 Multivariate analysis results
Number RR 95% CI
lower
limit
95% CI
upper
limit
P-value Overall
p value
Chronic GVHD
ATG/alemtuzumab
No 174 1 0.02
Yes 55 0.58 0.36 0.93 0.02
Progression/Relapse
No significant covariates
Non-relapse mortality
No significant covariates
Progression-free survival
Disease status
CR 108 1 0.03
PR 90 1.13 0.76 1.66 0.54
Chemoresistant 38 1.73 1.08 2.77 0.02
Missing/Untreated 13 0.43 0.15 1.20 0.11
Overall survival
Karnofsky performance
score (≤ 6 months)a
≥ 90% 119 1 0.002
< 90% 113 3.46 1.74 6.87 0.0004
Missing 17 1.95 0.54 6.98 0.31
Karnofsky performance
score (> 6 months)a
≥ 90% 106 1 0.28
< 90% 80 0.66 0.39 1.12 0.12
Missing 14 0.73 0.29 1.86 0.51
GVHD graft-versus-host disease, CI confidence interval, ATG anti-thymocyte
globulin, CR complete remission, PR partial remission, RR relative risk
Variables tested in the Multivariate analysis are listed in Additional file 1 Table S2
a6-months was chosen as cut-off based on the maximum likelihood value in
the Cox model
p-value <0.05 is considered significant
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was used to identify covariates that influenced outcomes.
Covariates with a p < 0.05 were considered statistically sig-
nificant. The proportional hazards assumption for Cox re-
gression was tested by adding a time-dependent covariate
for each risk factor and each outcome. If a variable violated
the proportional hazards assumption, it was added as a
time-varying covariate. Interactions between the main effect
and significant covariates were examined and none were
found. Results are expressed as relative risks (RR). The cen-
ter effect was examined using the random effect score test
[22] for OS, PFS, relapse, and NRM. The variables consid-
ered in multivariate analysis are shown in Additional file 1:
Table S2 of the supplemental appendix. All statistical ana-
lyses were performed using SAS version 9.4 (SAS Institute
Inc., Cary, NC).
Results
Baseline characteristics
A total of 249 patients met the inclusion criteria and were
included in this analysis. The baseline patient-, disease-,
and transplantation-related characteristics are shown in
Table 1. The median patient age was 56 years (range = 21–
77 years). Most of the patients were Caucasians (86%), with
a male (60%) predominance. The majority had a chemosen-
sitive disease at the time of allo-HCT (79%) and received a
non-myeloablative/reduced intensity conditioning regimen
(73%). Most common type of GVHD prophylaxis included
CNI ± methotrexate-based regimens. The graft source used
for allo-HCT was predominantly peripheral blood (97%).
Pre-transplant (allo-HCT) donor/recipient cytomegalovirus
status was available in 200 patients (81%) and the details
are provided in Table 1. There was no center effect noted
on the outcomes. Median follow-up of survivors was
49 months (range, 4–170 months).
Hematopoietic recovery
On univariate analysis, the cumulative incidence of neu-
trophil engraftment at 1-year was 97% (95% CI 94–99).
The 1-year cumulative incidence of platelet recovery
(Table 2) was 91% (95% CI 87–94).
Acute and chronic GVHD
On univariate analysis, the cumulative incidence of grade
II–IV acute GVHD was 36% (95% CI 30–42) and grades III–
IV acute GVHD was 12% (95% CI 8–17) at day 180 (Table
Fig. 1 Outcomes of patients receiving first allo-HCT for AITL. a Cumulative incidence of non-relapse mortality. b Cumulative incidence of lymphoma
progression/relapse. c Progression-free survival. d Overall survival
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2). None of the tested covariates (Additional file 1: Table S2)
affected the risk of the development of acute GVHD.
On univariate analysis, the cumulative incidence of
chronic GVHD at 1-year (Table 2) was 49% (95% CI 43–
56), while the cumulative incidence of extensive chronic
GVHD at 1 year (Table 2) was 39% (95% CI 33–46).
Multivariate analysis (Table 3) showed that patients who
received anti-thymocyte globulin (ATG) or alemtuzumab
had a significantly lower risk of chronic GVHD (RR =
0.58, 95% CI 0.36–0.93, p = 0.02) relative to those who
did not receive ATG/alemtuzumab.
Transplantation outcomes
On univariate analysis, the cumulative incidence of
1-year GRFS (Table 2) was 35% (95% CI 29–41).
The 1-year NRM rate (Table 2) was 19% (95% CI 14–24)
(Fig. 1a). On multivariate analysis, there were no significant
covariates affecting the risk of NRM. The cumulative inci-
dence of progression/relapse at 4 years (Table 2) was 21%
(95% CI 16–27) (Fig. 1b). On multivariate analysis (Table
3), none of the covariates (Additional file 1: Table S1,
including chronic GVHD assessed as a time-dependent
variable) significantly affected the relapse risk.
The 4-year PFS and OS (Table 2) were 47% (95% CI 41–
54) (Fig. 1c) and 56% (95% CI 49–63) (Fig. 1d), respectively.
On multivariate analysis (Table 3), chemoresistant status at
the time of allo-HCT significantly increased the risk for
therapy failure (inverse of PFS) (RR = 1.73 95% CI = 1.08–
2.77, p = 0.02), while KPS < 90% was associated with a sig-
nificantly higher risk of mortality (inverse of OS) in the first
6-months post allo-HCT (RR = 3.46 95% CI = 1.74–6.87,
p = 0.0004).
Causes of death
At last follow-up, 45% (n = 112) of allo-HCT recipients had
died (Additional file 1: Table S3). The most common cause
of death was organ failure, 20% (n = 22) followed by recur-
rent/progressive disease, 19% (n = 21). GVHD was the
cause of death in 17% (n = 19) and infectious complications
accounted for death in 15% (n = 17) of patients. The other
causes of death are listed in Additional file 1: Table S3.
Impact of prior autograft and disease status
Among the 249 patients who received first allo-HCT, 98
patients (39%) had received a prior auto-HCT. Univari-
ate analysis looking at the impact of prior auto-HCT (no
prior auto-HCT vs prior auto-HCT) on the outcomes
showed no significant difference in the 1-year NRM (17%
[95% CI 11–23] vs 22% [95% CI 14–30], p = 0.33), 4-year
progression/relapse (24% [95% CI 17–31] vs 17% [95% CI
Table 4 Comparative analysis of AITL patients who received prior auto-HCT vs no prior auto-HCT
Outcomes No prior auto-HCT (N = 151) Prior auto-HCT (N = 98) p value
N Prob (95% CI) N Prob (95% CI)
NRM 151 98 0.25
1-year 17 (11–23)% 22 (14–30)% 0.33
2-year 21 (15–28)% 31 (22–41)% 0.08
3-year 22 (16–29)% 33 (23–43)% 0.07
4-year 26 (19–34)% 36 (26–47)% 0.11
Progression/relapse 151 98 0.69
1-year 16 (11–22)% 15 (8–22)% 0.77
2-year 22 (15–29)% 16 (9–24)% 0.23
3-year 23 (16–30)% 17 (10–25)% 0.28
4-year 24 (17–31)% 17 (10–25)% 0.21
PFS 151 98 0.45
1-year 68 (60–75)% 64 (54–73)% 0.56
2-year 57 (49–65)% 53 (43–63)% 0.53
3-year 55 (47–64)% 50 (40–61)% 0.43
4-year 50 (42–59)% 47 (36–57)% 0.60
Overall survival 151 98 0.81
1-year 73 (65–80)% 74 (65–82)% 0.81
2-year 65 (57–72)% 59 (49–69)% 0.43
3-year 61 (53–69)% 58 (47–68)% 0.63
4-year 57 (49–65)% 54 (44–65)% 0.70
Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival, HCT hematopoietic cell transplantation
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10–25], p = 0.21), PFS (50% [95% CI 42–59] vs 47% [95%
CI 36–57], p = 0.60), or OS (57% [95% CI 49–65] vs 54%
[95% CI 44–65], p = 0.70) (Table 4, Fig. 2).
Among the 198 patients with chemosensitive disease
at the time of allo-HCT, 33 patients (17%) were in CR1,
while 75 patients (38%) were in CR > 1 and 90 patients
(45%) were in PR. Univariate analysis looking at the
effect of remission status at allo-HCT, CR1 vs CR > 1 vs
PR vs refractory (Table 5), showed a 4-year PFS of 58%
vs 45% vs 47% vs 38%, respectively, and a 4-year OS of
70% vs 54% vs 50% vs 52%, respectively. Among patients
with chemorefractory AITL, the 1-year NRM was 24%,
while the 4-year progression/relapse, PFS, and OS in
patients with refractory AITL were 32%, 38%, and 52%,
respectively. Figure 3 shows the disease outcomes for
AITL patients based on the remission status at allo-
HCT (CR vs PR vs chemoresistant).
Discussion
Prospective studies evaluating the outcomes of allo-HCT
exclusively in AITL have not been performed given an
overall rarity of this PTCL subtype. Here, we performed a
registry analysis of AITL patients receiving first allo-HCT
and made several important observations. First, allo-HCT
provided durable disease control in patients with AITL as
evidenced by 4-year PFS of 47%. Second, the risk of
relapse tended to plateau at 2-year post allo-HCT. Lastly,
allo-HCT provided durable disease control even in
patients with a failed prior auto-HCT and those subjects
with refractory disease at the time of allografting.
Auto-HCT has been previously studied as a consolida-
tion modality for patients with AITL in first CR and be-
yond. While auto-HCTcan provide durable disease control
in AITL subjects in CR1, the outcomes of patients not in
CR, or those with heavily pretreated disease are not opti-
mal [10]. In addition, despite low transplant-related mor-
tality, the risk of relapse following autografting remains
high (1- and 2-year relapse risk is 40% and 51%, respect-
ively) [10]. In contrast, allo-HCT provides excellent
survival outcomes for patients with AITL with a lower risk
of relapse. Additional file 1: Table S1 summarizes the retro-
spective studies (n ≥ 9) that have looked at the role of
Fig. 2 Outcomes of AITL patients based on the receipt of prior auto-HCT vs no prior auto-HCT. a Cumulative incidence of non-relapse mortality.
b Cumulative incidence of lymphoma progression/relapse. c Progression-free survival. d Overall survival
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allo-HCT in AITL [11, 14–16]. The current study is the
largest registry validation of these results showing durable
responses in patients with AITL following allo-HCT.
Though previous studies included patients with prior
auto-HCT failure and chemorefractory state, the data are
limited by very small patient numbers (for example, the
previously published study with a large number of AITL
patients [n = 45] included 15 patients with prior auto-HCT
failure and 18 patients with chemorefractory disease at
allo-HCT) [14] limiting the ability to draw meaningful
conclusions. Considering the fact that ASBMT Clinical
Practice Recommendation Panel [23] endorses the use of
auto-HCT in AITL patients in CR1/PR1, and the high
rates of disease relapse in patients receiving high-dose
therapy, addressing the role of a subsequent allo-HCT is a
clinically important question. In the current analysis, we
did not observe any statistically significant differences in
outcomes for patients who had prior auto-HCT vs no prior
auto-HCT. Our results support the curative potential of
allo-HCT in high-risk AITL patients who have failed a
prior auto-HCT.
Limited data are published on the role of allo-HCT in
refractory AITL. Registry data from the European Soci-
ety for Blood and Marrow Transplantation (EBMT)
identified chemorefractory disease as a predictor of
inferior outcomes but included only 18 refractory AITL
patients [14]. In the current analysis, the 4-year PFS and
OS of chemorefractory patients was 38% and 52%
respectively, which supports the use of allografting in
this ultra-high-risk subset of patients (who otherwise are
fit to undergo allo-HCT). In our study, we did not find a
relationship between chronic GVHD and relapse rate in
contrast to the previously reported data [14]. The retro-
spective nature of the registry data does not permit us to
analyze the optimal timing of allo-HCT. While the out-
comes of CR1 patients in the current study were favor-
able (4-year PFS and OS 58% and 70%), prior studies
have also suggested very encouraging outcomes of AITL
patients undergoing auto-HCT in CR1 [10, 24].
AITL is a challenging diagnosis with roughly only 80%
concordance even among expert pathologists with access
to archival tissue [3, 7]. One of the limitations of the
current study is the lack of central pathology review of
archival tissue for all patients. The current study in-
cluded cases as diagnosed by the pathologists at the re-
spective institutions. Of note, disease histology is one of
the critical fields CIBMTR examines during its onsite
transplant center audits (where diagnosis reported to
CIBMTR is audited relative to the pathology records
available at the reporting center). In recent CIBMTR
Table 5 Comparative analysis of AITL patients based on the remission status at the time of allo-HCT
CR1 (N = 33) CR > 1 (N = 75) PR (N = 90) Refractory (N = 38)
Outcomes N Prob (95% CI) N Prob (95% CI) N Prob (95% CI) N Prob (95% CI)
NRM 33 75 90 38
1-year 6 (1–17)% 20 (12–30)% 20 (13–29)% 24 (12–38)%
2-year 13 (4–26)% 29 (19–40)% 25 (17–35)% 30 (16–45)%
3-year 17 (6–32)% 31 (21–43)% 25 (17–35)% 30 (16–45)%
4-year 17 (6–32)% 36 (25–49)% 33 (22–44)% 30 (16–45)%
Progression/ relapse 33 75 90 38
1-year 15 (5–29)% 13 (7–22)% 14 (7–21)% 29 (16–44)%
2-year 25 (12–41)% 16 (9–26)% 19 (11–28)% 29 (16–44)%
3-year 25 (12–41)% 18 (10–28)% 19 (11–28)% 32 (18–48)%
4-year 25 (12–41)% 18 (10–28)% 21 (12–30)% 32 (18–48)%
PFS 33 75 90 38
1-year 79 (63–91)% 67 (56–77)% 66 (56–76)% 47 (32–63)%
2-year 62 (45–78)% 54 (43–66)% 56 (45–66)% 41 (26–57)%
3-year 58 (41–75)% 50 (38–62)% 56 (45–66)% 38 (23–54)%
4-year 58 (41–75)% 45 (33–58)% 47 (36–58)% 38 (23–54)%
Overall survival 33 75 90 38
1-year 88 (75–97)% 73 (63–83)% 71 (61–80)% 63 (47–78)%
2-year 78 (62–90)% 62 (51–73)% 59 (48–69)% 52 (36–67)%
3-year 70 (52–85)% 58 (46–70)% 57 (47–68)% 52 (36–67)%
4-year 70 (52–85)% 54 (41–66)% 50 (39–62)% 52 (36–67)%
CR complete response, PR partial response, Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival
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studies involving rare T-cell histologies, > 95% concord-
ance was seen between center-reported diagnosis and cen-
tral review of pathology reports [25, 26]. We acknowledge
that this analysis is not a substitute of central review of
archival tissue by expert pathologists. At the same time, it
is important to note that the majority of prospective clin-
ical trials enrolling AITL subjects accept the patients
based on the pathology reports at the participating sites,
without a mandatory central review of archival tissue. In
addition, the CIBMTR registry does not capture
post-relapse salvage therapy, thereby limiting the ability to
assess the post allo-HCT relapse survival.
Conclusions
With a better understanding of the biology and develop-
ment of prognostic tools, there has been a major effort to
study novel drug combinations and immunotherapy agents
(including checkpoint inhibitors and chimeric antigen re-
ceptor T-cell [CAR-T] therapy) in patients with NHL.
Brentuximab vedotin (anti-CD30 antibody-drug conjugate)
is being studied in combination with chemotherapy in the
frontline setting in PTCL patients (ECHELON 2 trial,
NCT 01777152). The final results are eagerly awaited to
assess the impact of CD30-directed therapies in the subset
of AITL patients. While the data on CAR-T cell therapy
for B-cell NHL (mainly diffuse large B-cell lymphoma) in
the relapsed/refractory setting is impressive [27], similar
constructs in T-cell NHL have not been translated to the
bedside. Our results suggest that allo-HCT offers the po-
tential for cure in AITL patients including those with
otherwise chemo-refractory disease. In the foreseeable fu-
ture, allo-HCT is likely to remain an important therapeutic
option for AITL patients.
Additional file
Additional file 1: Table S1. Outcomes of patients with AITL who
underwent allogeneic HCT. Table S2. Variables tested in Cox
proportional hazards regression models. Table S3. Causes of Death.
Table S4. Conditioning Intensity. Table S5. Details of GVHD prophylaxis
regimens. Table S6. Univariate outcomes of AITL patients receiving
alternative donor sources. (DOCX 29 kb)
Fig. 3 Outcomes of AITL patients based on the disease status at allo-HCT. a Cumulative incidence of non-relapse mortality. b Cumulative
incidence of lymphoma progression/relapse. c Progression-free survival. d Overall survival
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